BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. Its pipeline includes BRTX-100, a lead cell therapy candidate made from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, intended for non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapy to surgery, and ThermoStem, a cell-based therapy candidate targeting obesity and metabolic disorders using brown adipose-derived stem cells to generate brown adipose tissue. The company also operates a commercial biocosmeceutical platform and provides an investigational curved needle device to deliver cells and/or other therapeutic products or material to the spine, discs, and other parts of the body. Formerly known as Stem Cell Assurance, Inc., it changed its name to BioRestorative Therapies, Inc. in August 2011 and is headquartered in Melville, New York.